arrow_back Back to App

Supporting Fungal Disease Research and Drug Development

This act aims to boost research into rare fungal diseases, such as Valley Fever, and accelerate the development of new treatments and vaccines. This means potentially better diagnostics, more effective treatments, and improved health security for citizens at risk of these conditions. A dedicated working group will be established to coordinate these efforts and advise on research priorities.
Key points
Increased funding for research into fungal diseases, including Valley Fever, potentially leading to new treatments.
Establishment of an expert working group to coordinate efforts and advise on combating fungal diseases.
Expansion of incentive programs for pharmaceutical companies to accelerate the development of drugs and vaccines for these diseases.
Support for programs combating antimicrobial resistance, including antifungal medications.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_6731
Sponsor: Rep. Schweikert, David [R-AZ-1]
Process start date: 2023-12-12
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

FORWARD Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_6731.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-12-12.

What are the main provisions?

Key points include:

  • Increased funding for research into fungal diseases, including Valley Fever, potentially leading to new treatments.
  • Establishment of an expert working group to coordinate efforts and advise on combating fungal diseases.
  • Expansion of incentive programs for pharmaceutical companies to accelerate the development of drugs and vaccines for these diseases.
  • Support for programs combating antimicrobial resistance, including antifungal medications.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Schweikert, David [R-AZ-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health